Skip to Content
Hae Menu

The first-in-class antibody talquetamab show a high clinical response rate in patients with relapsed and refractory multiple myeloma

Talquetamab is a first-in-class bispecific immunoglobulin G4 antibody that binds to CD3 and GPRC5D for activating T cells to attack multiple myeloma cells. The phase I study MonumentTAL-1 has shown high clinical response rate in patients with relapsed and refractory multiple myeloma.

Avaa artikkeli

Jos olet lääkäri, sairaanhoitaja tai muu terveydenhuollon ammattilainen, voit käyttää koko artikkelia luomalla profiilin BestPractice Nordic -sivustolle.

Asiaan liittyvä sisältö

Azacitidine was generally well tolerated in patients ≥ 75 years of age in QUAZAR AML-001

/ BestPractice Nordic
EHA21AML

CAR-T cell therapy provides early and deep response in multiple myeloma patients

/ BestPractice Nordic
myeloomaEHA21

mutNPM1 status is a prognostic and an independent predictive marker for improved survival with azacitidine

/ BestPractice Nordic
EHA21AML
Back to top